|
Market Closed -
Nasdaq
04:00:00 2026-05-07 pm EDT
|
Pre-market
08:22:22 am
|
|
219.82 USD
|
+2.20%
|
 |
223.94 |
+1.87%
|
|
May. 07 |
Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours
|
MT
| |
May. 07 |
(NTRA) Natera Expects Full Year 2026 Revenue Range $2.74B - $2.82B, vs. FactSet Est of $2.67B
|
MT
| |
May. 07 |
Earnings Flash (NTRA) Natera Posts Q1 Loss $0.60, vs. FactSet Est of $0.54 Loss
|
MT
| |
May. 07 |
Earnings Flash (NTRA) Natera, Inc. Reports Q1 Revenue $696.6M, vs. FactSet Est of $617.1M
|
MT
| |
May. 07 |
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
Apr. 22 |
Natera, Inc. Features Prospera Evidence In Heart And Lung Transplantation Across 17 Presentations at ISHLT
|
CI
| |
Apr. 09 |
Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales
|
MT
| |
Mar. 31 |
Natera Inc Announces Signatera MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
|
CI
| |
Mar. 16 |
Natera Inc Highlights Clinical Utility of Signatera in Anal and Rectal Cancers
|
CI
| |
Mar. 12 |
Natera Inc Announces Commercial Launch of Zenith Genomics
|
CI
| |
Mar. 12 |
Natera and Myome Enter Strategic Alliance for Rare Disease Genomics
|
CI
| |
Feb. 27 |
Signatera?? Mrd Data At Asco Gu Highlights Potential Utility Across Gu Cancers, Including for Bladder Preservation
|
CI
| |
Feb. 26 |
Natera Q4 Operating Loss Narrows, Revenue Rises
|
MT
| |
Feb. 26 |
(NTRA) Natera Expects 2026 Revenue Range $2.62B - $2.70B, vs. FactSet Est. of $2.61B
|
MT
| |
Feb. 26 |
Earnings Flash (NTRA) Natera, Inc. Reports Q4 Revenue $665.5M, vs. FactSet Est of $604.0M
|
MT
| |
Feb. 26 |
Natera, Inc. Provides Earnings Guidance for the Year 2026
|
CI
| |
Feb. 26 |
Natera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
Feb. 24 |
Natera, Inc. Announces Results from the Sinergy Trial
|
CI
| |
Feb. 06 |
Natera, Inc. Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
|
CI
| |
Feb. 02 |
Natera submits Signatera(TM) CDx PMA to FDA
|
RE
| |
Feb. 02 |
Natera, Inc. Submits Signatera CDx PMA to FDA
|
CI
| |
Jan. 28 |
Natera Announces Completion of Enrollment in Randomized ACES-EMBTrial in Heart Transplantation
|
CI
| |
Jan. 21 |
Natera, Inc. Publishes Clinical Validation of Latitude?? Tissue-Free MRD Test in Colorectal Cancer
|
CI
| |
Jan. 13 |
Natera Unveils AI Model to Enhance Cancer Recurrence Risk Assessment
|
MT
| |
Jan. 13 |
Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
